ライフサイエンスコーパス: macrophage colony-stimulating factor

1 ytokine responses (Th1, Th2, and granulocyte-macrophage colony-stimulating factor).

2 ytokines (monocyte chemotactic protein-1 and macrophage colony-stimulating factor).

3 ANVAC with per injection GM-CSF (granulocyte-macrophage colony-stimulating factor).

4 CXCL8, CCL2, interleukin-6, and granulocyte-macrophage colony stimulating factor.

5 on and produced IL-22, IL-8, and granulocyte macrophage colony stimulating factor.

6 an alveolar-like phenotype with granulocyte-macrophage colony-stimulating factor.

7 further enhancement of IL-10 and granulocyte-macrophage colony-stimulating factor.

8 tumor necrosis factor-alpha and granulocyte macrophage colony-stimulating factor.

9 acquisition of responsiveness to granulocyte-macrophage colony-stimulating factor.

10 uction of IFN-gamma, IL-17A, and granulocyte-macrophage colony-stimulating factor.

11 ivator of nuclear factor kappa-B ligand, and macrophage colony-stimulating factor.

12 tion, bacterial infection, starvation and by macrophage colony-stimulating factor.

13 nd (C-C motif) ligand 2, and the granulocyte macrophage colony-stimulating factor.

14 lodronate treatment or genetic deficiency of macrophage colony-stimulating factor.

15 ic differentiation from the cells induced by macrophage colony-stimulating factor.

16 of inflammatory signals such as granulocyte-macrophage colony-stimulating factor.

17 l other treatments except CTLA-4/granulocyte macrophage colony-stimulating factor.

18 tumor necrosis factor alpha, and granulocyte-macrophage colony-stimulating factor.

19 thogenesis and possibly also for granulocyte-macrophage colony-stimulating factor.

20 es interleukin (IL)-6, IL-7, and granulocyte macrophage-colony-stimulating factor.

21 ation and is a signaling effector engaged by macrophage colony-stimulating factor 1 (CSF-1) and recep

22 e were given neutralizing antibodies against macrophage colony-stimulating factor 1 (CSF1 or MCSF) or

23 Production of macrophage colony-stimulating factor 1 (CSF1) by BCCs is

24 ABT induced the tumor cells to express macrophage colony-stimulating factor 1 (M-CSF1 or CSF1)

25 igh-affinity ligand that is specific for the macrophage colony-stimulating factor 1 receptor (CSF1R),

26 nfirmed by results of studies inhibiting the macrophage colony-stimulating factor 1 receptor,whereas

27 eeks) to one metastatic site and granulocyte-macrophage colony-stimulating factor (125 mug/m(2) subcu

28 g/m(2) per day) on days 2-5 plus granulocyte macrophage colony-stimulating factor (250 mug/m(2) per d

29 CI -12.4, -33.2 [P = 0.004]) for granulocyte-macrophage colony-stimulating factor, -33.4% (95% CI -20

30 inations of IMA901 (4.13 mg) and granulocyte macrophage colony-stimulating factor (75 mug), with one

31 age colony-stimulating factor or granulocyte-macrophage colony-stimulating factor, all of which stimu

32 to B7-H1, partially due to its induction by macrophage colony-stimulating factor and downregulation

33 and cultured in the presence of granulocyte-macrophage colony-stimulating factor and hepatic stellat

34 made foamy macrophages easily in vitro with macrophage colony-stimulating factor and human serum.

35 7 T cells secrete cytokines (eg, granulocyte-macrophage colony-stimulating factor and interferon-gamm

36 emotactic protein-1, and reduced granulocyte-macrophage colony-stimulating factor and macrophage infl

37 alyzed) had reduced responses to granulocyte-macrophage colony-stimulating factor and markedly decrea

38 The combined presence of macrophage colony-stimulating factor and receptor activa

39 ely produce human interleukin-3, granulocyte-macrophage colony-stimulating factor and Steel factor (N

40 aracterized by the expression of granulocyte-macrophage colony-stimulating factor and the C-X-C chemo

41 ired high langerin and CD1a with granulocyte-macrophage colony-stimulating factor and transforming gr

42 led to a correlative decrease in granulocyte-macrophage colony-stimulating factor and white blood cel

43 expression of microglial chemokines, such as macrophage-colony-stimulating factor and monokine induce

44 nflammatory protein (MIP)-1beta, granulocyte macrophage colony-stimulating factor) and adaptive cytok

45 n-gamma, tissue necrosis factor, granulocyte-macrophage colony-stimulating factor) and cytolytic degr

46 leukin-1beta, interleukin-6, and granulocyte macrophage colony-stimulating factor) and hypothermia at

47 perfamily, to antagonize GM-CSF (granulocyte macrophage colony-stimulating factor) and IL-2 (interleu

48 tration, upregulation of cytokines including macrophage colony-stimulating factor, and 3-fold increas

49 ocyte-colony stimulating factor, granulocyte-macrophage colony-stimulating factor, and C-reactive pro

50 ma, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and granzyme B), a

51 uding growth-regulated oncogene, granulocyte macrophage colony-stimulating factor, and IL-1beta.

52 matory protein 1alpha and 1beta, granulocyte-macrophage colony-stimulating factor, and interferon-gam

53 -1beta), hematopoietic IL-7, and granulocyte macrophage colony-stimulating factor, and regulatory IL-

54 nterleukin 17, interferon gamma, granulocyte-macrophage colony-stimulating factor, and tumor necrosis

55 Interferon-gamma and granulocyte-macrophage colony-stimulating factor are requisite facto

56 (Arm V; n = 432), PROSTVAC plus granulocyte-macrophage colony-stimulating factor (Arm VG; n = 432),

57 sine carboxymethylcellulose) and granulocyte-macrophage colony-stimulating factor as adjuvants displa

58 autologous dendritic cells, and granulocyte-macrophage colony-stimulating factor at the same site.

59 ontuberculous mycobacteria; anti-granulocyte macrophage colony-stimulating factor autoantibodies and

60 d performed B-cell depletion and granulocyte-macrophage colony-stimulating factor blockade.

61 c cells (DCs) when cultured with granulocyte macrophage-colony-stimulating factor but not with other

62 sults in sustained expression of granulocyte-macrophage colony-stimulating factor by renal tubular ce

63 IL-12, IL-17, gamma interferon, granulocyte-macrophage colony-stimulating factor) by CD4(+) and CD8(

64 eptidoglycan, dexamethasone, and granulocyte-macrophage colony stimulating factor, by driving apoptos

65 ression of the interleukin 3 and granulocyte/macrophage-colony stimulating factor common beta-chain r

66 ed pSTAT5 after stimulation with granulocyte-macrophage colony-stimulating factor, compared with cell

67 te colony-stimulating factor and granulocyte-macrophage colony-stimulating factor), consistent with a

68 creased the expression levels of granulocyte-macrophage colony-stimulating factor (CSF), granulocyte

69 Genetic or pharmacologic inhibition of macrophage colony-stimulating factor (CSF-1) signaling b

70 We have previously shown that macrophage colony-stimulating factor (CSF-1; M-CSF) dire

71 by reducing the expression and secretion of macrophage colony-stimulating factor CSF1 by tumor cells

72 Cytokine analysis showed that the macrophage colony-stimulating factor CSF1 increased by t

73 mbers of liver macrophages are controlled by macrophage colony-stimulating factor (CSF1).

74 ytes depend on signals from the receptor for macrophage colony-stimulating factor, CSF1R.

75 on of Il17a, Csf2 (which encodes granulocyte-macrophage colony-stimulating factor), Cxcl1, and Cxcl5,

76 eric mice lacking B cell-derived granulocyte macrophage colony-stimulating factor develop smaller les

77 IFN-gamma enhanced bacterial replication in macrophage colony-stimulating factor-differentiated macr

78 ntiated macrophages more than in granulocyte-macrophage colony-stimulating factor-differentiated macr

79 We report that in tumor-bearing mice the macrophage colony-stimulating factor elevates the myeloi

80 ctor, granulocyte colony-stimulating factor, macrophage colony-stimulating factor, eotaxin, interfero

81 GVAX vaccination (consisting of granulocyte macrophage colony-stimulating factor-expressing irradiat

82 AP due to autoantibodies against granulocyte-macrophage colony-stimulating factor; genetic mutations

83 Recently, granulocyte-macrophage colony stimulating factor (GM-CSF) has been i

84 have analyzed the involvement of granulocyte-macrophage colony stimulating factor (GM-CSF) in nocicep

85 ects treated with Ipilimumab and granulocyte macrophage colony stimulating factor (GM-CSF) was presen

86 lony stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), IL-8, IL-

87 crosis factor alpha (TNF-alpha), granulocyte macrophage colony stimulating factor (GM-CSF), interleuk

88 se of high immunogenic levels of granulocyte-macrophage colony stimulating factor (GM-CSF), through d

89 ce the pro-inflammatory cytokine granulocyte-macrophage colony stimulating factor (GM-CSF).

90 Granulocyte-macrophage colony-stimulating factor (GM-CSF or Csf-2) i

91 matory response, as decreases in granulocyte-macrophage colony-stimulating factor (GM-CSF) (6.6-fold)

92 The cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) (encoded b

93 pressing interleukin (IL)-12 and granulocyte-macrophage colony-stimulating factor (GM-CSF) (oAd) and

94 9513 had increased TNF-alpha and Granulocyte-macrophage colony-stimulating factor (GM-CSF) (P </= 0.0

95 tered intradermally with 200 mug granulocyte-macrophage colony-stimulating factor (GM-CSF) adjuvant o

96 oinflammatory mediators, such as granulocyte-macrophage colony-stimulating factor (GM-CSF) and C-C mo

97 (TM) peptide hydrogel containing granulocyte macrophage colony-stimulating factor (GM-CSF) and CpG OD

98 in the presence of the cytokines granulocyte-macrophage colony-stimulating factor (GM-CSF) and interl

99 nsively studied, others, such as granulocyte-macrophage colony-stimulating factor (GM-CSF) and interl

100 er coculture with breast cancer: granulocyte macrophage colony-stimulating factor (GM-CSF) and matrix

101 trial to evaluate the effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) and peptid

102 senting distinct combinations of granulocyte macrophage colony-stimulating factor (GM-CSF) and variou

103 re, we investigated neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) as a poten

104 es IL-17A, IFN-gamma, IL-22, and granulocyte-macrophage colony-stimulating factor (GM-CSF) as well as

105 ninfected adults, including anti-granulocyte macrophage colony-stimulating factor (GM-CSF) autoantibo

106 rs of the interleukin-23 (IL-23)-granulocyte macrophage colony-stimulating factor (GM-CSF) axis in co

107 nterferon (IFN-gamma), CCL4, and granulocyte-macrophage colony-stimulating factor (GM-CSF) by CD8(+)

108 d had reduced productions of the granulocyte-macrophage colony-stimulating factor (GM-CSF) by central

109 s such as CCL-3 (MIP-1alpha) and granulocyte-macrophage colony-stimulating factor (GM-CSF) can enhanc

110 l studies have demonstrated that granulocyte macrophage colony-stimulating factor (GM-CSF) can functi

111 hrough injection of WT mice with granulocyte-macrophage colony-stimulating factor (GM-CSF) DNA reduce

112 ontext, interleukin 4 (IL-4) and granulocyte macrophage colony-stimulating factor (GM-CSF) drive dend

113 Priming with cytokines such as granulocyte-macrophage colony-stimulating factor (GM-CSF) enhances e

114 porous alginate gels loaded with granulocyte-macrophage colony-stimulating factor (GM-CSF) for concen

115 Benefits of granulocyte-macrophage colony-stimulating factor (GM-CSF) for improv

116 Granulocyte-macrophage colony-stimulating factor (GM-CSF) has many m

117 Growing evidence shows that granulocyte macrophage colony-stimulating factor (GM-CSF) has progre

118 e identify an essential role for granulocyte/macrophage colony-stimulating factor (GM-CSF) in orchest

119 oduction of the potent chemokine granulocyte macrophage colony-stimulating factor (GM-CSF) in respons

120 granulocytes in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) in vitro.

121 Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a medic

122 Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a multi

123 Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a pleio

124 Here we show that granulocyte macrophage colony-stimulating factor (GM-CSF) is a trigg

125 of the pro-inflammatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) is EGFR de

126 udies suggest that the increased granulocyte-macrophage colony-stimulating factor (GM-CSF) level in t

127 Adaptive CD4(+) T cells produced granulocyte-macrophage colony-stimulating factor (GM-CSF) on restimu

128 neutralizing antibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF) or tumor n

129 iDCs by interleukin-4 (IL-4) and granulocyte-macrophage colony-stimulating factor (GM-CSF) over 7 day

130 Granulocyte macrophage colony-stimulating factor (GM-CSF) plays a ce

131 O, we tested the pro-M1 cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) plus block

132 Granulocyte-macrophage colony-stimulating factor (GM-CSF) produced b

133 terleukin (IL)-1beta that drives granulocyte-macrophage colony-stimulating factor (GM-CSF) production

134 Here, we show that deficient granulocyte-macrophage colony-stimulating factor (GM-CSF) production

135 s highlight surprising roles for granulocyte-macrophage colony-stimulating factor (GM-CSF) production

136 that donor T cells that secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) promote gr

137 lar proteinosis (hPAP) caused by granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor a

138 Here, using granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor-b

139 ny-stimulating factor (M-CSF) or granulocyte macrophage colony-stimulating factor (GM-CSF) resembled

140 ing SAA treatment or blockade of granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling

141 is (PAP) syndrome, disruption of granulocyte/macrophage colony-stimulating factor (GM-CSF) signaling

142 nhances respiratory defenses via granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling,

143 ols IgM production via autocrine granulocyte/macrophage colony-stimulating factor (GM-CSF) signaling.

144 Granulocyte-macrophage colony-stimulating factor (GM-CSF) signalling

145 aracterized by the disruption of granulocyte-macrophage colony-stimulating factor (GM-CSF) signalling

146 ouse cardiac fibroblasts produce granulocyte/macrophage colony-stimulating factor (GM-CSF) that acts

147 ole limpet hemocyanin (KLH) plus granulocyte macrophage colony-stimulating factor (GM-CSF) to a contr

148 licate within tumors and produce granulocyte macrophage colony-stimulating factor (GM-CSF) to enhance

149 rine bone marrow (BM) cells with granulocyte-macrophage colony-stimulating factor (GM-CSF) to generat

150 tested the hypotheses that human granulocyte-macrophage colony-stimulating factor (GM-CSF), a clinica

151 Granulocyte-macrophage colony-stimulating factor (GM-CSF), a myelopo

152 talloproteinase (MMP)-9, IL-1Ra, granulocyte-macrophage colony-stimulating factor (GM-CSF), and C-rea

153 lony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and CXCL1

154 city, constitutive activation of granulocyte macrophage colony-stimulating factor (GM-CSF), and enhan

155 xposure to interleukin-3 (IL-3), granulocyte-macrophage colony-stimulating factor (GM-CSF), and stem

156 tinuous action of both FLT3L and granulocyte macrophage colony-stimulating factor (GM-CSF), explained

157 Granulocyte-macrophage colony-stimulating factor (GM-CSF), mainly pr

158 uction of the chemokine CCL2 and granulocyte-macrophage colony-stimulating factor (GM-CSF), respectiv

159 nd interleukin-4 (IL-4), but not granulocyte-macrophage colony-stimulating factor (GM-CSF), signaling

160 ccine that delivers the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), the Toll-

161 en cultured with soluble ligands granulocyte macrophage colony-stimulating factor (GM-CSF), transform

162 w progenitors in the presence of granulocyte/macrophage colony-stimulating factor (GM-CSF), we used G

163 including neurotrophins and the granulocyte-macrophage colony-stimulating factor (GM-CSF)-CC-chemoki

164 of FGL2 in tumor cells inhibited granulocyte-macrophage colony-stimulating factor (GM-CSF)-induced CD

165 ed macrophages (MDMs), including granulocyte macrophage colony-stimulating factor (GM-CSF)-polarized

166 CTLA-4 blockade and granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting

167 e alveolar epithelium to produce granulocyte-macrophage colony-stimulating factor (GM-CSF).

168 which is induced by exposure to granulocyte-macrophage colony-stimulating factor (GM-CSF).

169 tokines such as IL-2, IL-15, and granulocyte-macrophage colony-stimulating factor (GM-CSF).

170 ing treatment with IL-3, IL-5 or granulocyte-macrophage colony-stimulating factor (GM-CSF).

171 be dependent on TH cell-derived granulocyte-macrophage colony-stimulating factor (GM-CSF).

172 on of human blood monocytes with granulocyte-macrophage colony-stimulating factor (GM-CSF).

173 on of interleukin 12 (IL-12) and granulocyte-macrophage colony-stimulating factor (GM-CSF).

174 caused by autoantibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF).

175 acterized by hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF).

176 t (RORgammat), IL-17, IL-22, and granulocyte macrophage colony-stimulating factor (GM-CSF).

177 d Bim, and this was inhibited by granulocyte-macrophage colony-stimulating factor (GM-CSF).

178 nes such as RORgammat, CCR6, and granulocyte macrophage colony-stimulating factor (GM-CSF).

179 aracteristic hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF).

180 erated from bone marrow cells by granulocyte-macrophage colony-stimulating factor (GM-CSF)/G-CSF in v

181 1alphaP (CCL3L1), and MIP-1beta; granulocyte-macrophage colony-stimulating factor (GM-CSF); lymphotac

182 Granulocyte macrophage colony-stimulating factor (GM-CSF, Csf2) is a

183 Granulocyte-macrophage colony-stimulating factor (GM-CSF/CSF2) is a

184 mal lower abdominal injection of granulocyte-macrophage colony-stimulating factor (GM-CSF; 75 mug) an

185 We hypothesized that targeting granulocyte-macrophage colony-stimulating factor (GM-CSF; an agonist

186 s] with PSC supernatants or IL-6/granulocyte macrophage colony-stimulating factor (GM-CSF; positive c

187 Here we report that human granulocyte macrophage-colony stimulating factor (GM-CSF) can sensit

188 The pleiotropic cytokine granulocyte macrophage-colony stimulating factor (GM-CSF) enhances a

189 To determine mechanisms by which granulocyte/macrophage-colony stimulating factor (GM-CSF) signaling

190 onal myeloid progenitor cells to granulocyte macrophage-colony stimulating factor (GM-CSF) via a larg

191 colitis depends on production of granulocyte macrophage-colony stimulating factor (GM-CSF), which rec

192 es interleukin (IL)-3, IL-5, and granulocyte macrophage-colony-stimulating factor (GM-CSF) and can re

193 ndothelial growth factor but not granulocyte macrophage-colony-stimulating factor (GM-CSF) and induce

194 trating that mutant Shp2 induces granulocyte macrophage-colony-stimulating factor (GM-CSF) hypersensi

195 n-of-function (GOF) Shp2-induced granulocyte macrophage-colony-stimulating factor (GM-CSF) hypersensi

196 Granulocyte-macrophage-colony-stimulating factor (GM-CSF) hypersensi

197 ypersensitivity of JMML cells to granulocyte macrophage-colony-stimulating factor (GM-CSF), a unifyin

198 Flt3) ligand-induced, but not in granulocyte macrophage-colony-stimulating factor (GM-CSF)-induced DC

199 DG172 strongly augmented granulocyte-macrophage-colony-stimulating factor (GM-CSF)-induced di

200 lammatory (interleukin-6 [IL-6], granulocyte-macrophage colony-stimulating factor [GM-CSF], CCL3, CCL

201 rleukin 10 [IL-10], IL-13, IL-6, granulocyte-macrophage colony-stimulating factor [GM-CSF], IL-4, and

202 enes coding for proinflammatory (granulocyte-macrophage colony-stimulating factor [GM-CSF], macrophag

203 ations than controls (n = 42) of granulocyte-macrophage colony-stimulating factor [(GM-CSF) 16.2 fold

204 ne-profiling assay, we show that granulocyte-macrophage colony-stimulating factor (GMCSF) is a key CR

205 0), IL-13, TNF-alpha, IFN-gamma, granulocyte-macrophage colony-stimulating factor, granulocyte colony

206 n, temozolomide, dintuximab, and granulocyte-macrophage colony-stimulating factor (I/T/DIN/GM-CSF) de

207 IL-17A, IL-22, interferon-gamma, granulocyte macrophage colony-stimulating factor, IL-13).

208 ation increased the secretion of granulocyte macrophage-colony stimulating factor, IL-12, -13, and -1

209 k, whereas vasopressin decreased granulocyte-macrophage colony-stimulating factor in patients who had

210 When osteoclast precursors were induced by macrophage colony-stimulating factor in the presence of

211 uced LHPC proliferation, whereas granulocyte-macrophage-colony stimulating factor induced differentia

212 nic cytokine (interleukin-4 plus granulocyte macrophage-colony stimulating factor)-induced activation

213 or activator of nuclear factor kappaB ligand/macrophage colony-stimulating factor induction of nuclea

214 n degranulation and secretion of granulocyte-macrophage colony-stimulating factor, interferon gamma,

215 ytokines and chemokines, such as granulocyte macrophage colony-stimulating factor, interferon-gamma,

216 s produced by T-helper 17 cells (granulocyte-macrophage colony-stimulating factor, interleukin [IL]17

217 ungs, constitutive expression of granulocyte-macrophage colony-stimulating factor, interleukin-18, in

218 interleukin-10, interleukin-17, granulocyte-macrophage colony-stimulating factor, interleukin-1beta,

219 s of various cytokines including granulocyte-macrophage colony-stimulating factor, interleukin-6 (IL-

220 High levels of serum cytokines (granulocyte macrophage colony-stimulating factor, interleukin-6, int

221 f the common beta subunit of the granulocyte-macrophage colony-stimulating factor/interleukin-3 recep

222 Granulocyte-macrophage colony-stimulating factor is a potent stimula

223 Granulocyte-macrophage colony-stimulating factor is a potential ther

224 asts for 21 days in-vitro in the presence of macrophage colony stimulating factor (M-CSF) and recepto

225 Macrophage colony stimulating factor (M-CSF) was implica

226 omoting cytokines [interleukin (IL-6), VEGF, macrophage colony-stimulating factor (M-CSF) ] and chemo

227 rophages and macrophages differentiated with macrophage colony-stimulating factor (M-CSF) alone (term

228 d osteoclastogenesis medium with 20 ng/mL of macrophage colony-stimulating factor (M-CSF) and 50 ng/m

229 ic phenotypes of macrophages stimulated with macrophage colony-stimulating factor (M-CSF) and granulo

230 fibrosis stages have higher serum levels of macrophage colony-stimulating factor (M-CSF) and interle

231 The molecular interactions between macrophage colony-stimulating factor (M-CSF) and the tyr

232 or of nuclear factor kappa B ligand (RANKL), macrophage colony-stimulating factor (M-CSF) and transfo

233 or activator of NF-kappaB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) as well as

234 ne C-Fms (C-Fms) and hyper-responsiveness to macrophage colony-stimulating factor (M-CSF) in bone mar

235 Here, we investigated the role of macrophage colony-stimulating factor (M-CSF) in TAM diff

236 nsforming growth factor-beta (TGF-beta), and macrophage colony-stimulating factor (M-CSF) levels.

237 the effects of stimulating macrophages with macrophage colony-stimulating factor (M-CSF) on muscle r

238 demonstrate that monocytes differentiated by macrophage colony-stimulating factor (M-CSF) or granuloc

239 axonal spheroids (HDLS), which is caused by macrophage colony-stimulating factor (M-CSF) receptor mu

240 timulation of hematopoietic progenitors with macrophage colony-stimulating factor (M-CSF) resulted in

241 The efficacy of a preventive macrophage colony-stimulating factor (M-CSF) treatment w

242 or activator of NF-kappaB ligand (RANKL) and macrophage colony-stimulating factor (m-CSF), critical o

243 ochastic cellular proliferation in situ in a macrophage colony-stimulating factor (M-Csf)- and granul

244 We generated macrophage colony-stimulating factor (M-CSF)-derived mon

245 stimulating factor (GM-CSF)-polarized M1 and macrophage colony-stimulating factor (M-CSF)-polarized M

246 Absence of TLN1 impairs macrophage colony-stimulating factor (M-CSF)-stimulated

247 (RANKL), either alone or in the presence of macrophage colony-stimulating factor (M-CSF).

248 gulation of macrophage glucose metabolism by macrophage colony-stimulating factor (M-CSF; inflammatio

249 The secondary outcome was the production of macrophage-colony stimulating factor (M-CSF) and tumor n

250 ast formation and functions are regulated by macrophage-colony-stimulating factor (M-CSF) and recepto

251 on of serum IFNgamma IL-10, GzB, granulocyte macrophage colony-stimulating factor, macrophage inflamm

252 First, macrophage colony stimulating factor (MCSF) secreted by

253 e profiled 48 serum cytokines and identified macrophage colony-stimulating factor (MCSF) as one of th

254 ses of amphotericin B and another activator, macrophage colony-stimulating factor (MCSF), further ele

255 crophage colony-stimulating factor [GM-CSF], macrophage colony-stimulating factor [MCSF], interleukin

256 nic effects of radiotherapy with granulocyte-macrophage colony-stimulating factor might result in abs

257 of a complex lasso glycoprotein, granulocyte-macrophage colony-stimulating factor, modeling both redu

258 mor necrosis factor (TNF) alpha, granulocyte-macrophage colony-stimulating factor, monocyte chemoattr

259 Interleukin-4, interleukin-8, granulocyte macrophage colony-stimulating factor, monocyte chemotact

260 B-cell depletion or granulocyte-macrophage colony-stimulating factor neutralization inhi

261 strated that, when cultured with granulocyte macrophage-colony-stimulating factor, neutrophils can gi

262 irradiated ID8 cells expressing granulocyte macrophage colony-stimulating factor or FLT3 ligand) and

263 t of CUS-exposed mice with either endotoxin, macrophage colony-stimulating factor or granulocyte-macr

264 n in vivo systemic inhibition of granulocyte-macrophage colony-stimulating factor or interferon-gamma

265 e (PI3K) effector Akt induced by granulocyte-macrophage colony-stimulating factor or interleukin-4.

266 r (GM-CSF) plus blockade of the M2 cytokines macrophage colony-stimulating factor or MIF.

267 C motif) ligand 5 (P < 0.01) and granulocyte-macrophage colony-stimulating factor (P < 0.001), thus c

268 of nuclear factor-kappaB ligand (RANKL) and macrophage colony-stimulating factor produced more TRAP(

269 combination of radiotherapy with granulocyte-macrophage colony-stimulating factor produced objective

270 nd 3-fold upregulated numbers of granulocyte-macrophage colony-stimulating factor-producing B cells w

271 Granulocyte macrophage colony-stimulating factor-producing IRA B cel

272 ers interferon-gamma, IL-15, and granulocyte-macrophage colony-stimulating factor protected from subs

273 utation had reduced responses to granulocyte-macrophage colony-stimulating factor, providing an addit

274 n-3 receptor [IL-3R], IL-5R, and granulocyte-macrophage colony stimulating factor receptor) signaling

275 ase, fatty acid binding protein, cadherin-5, macrophage colony-stimulating factor receptor (MCSFR), p

276 ; P < 0.0001); and expression of granulocyte-macrophage colony-stimulating factor receptor beta subun

277 ting factor receptor family (CSF3R/CSF3) and macrophage colony-stimulating factor receptor family (CS

278 MacGreen reporter mice (mice expressing the macrophage colony-stimulating factor receptor GFP transg

279 ciency to increase interleukin 3/granulocyte-macrophage colony-stimulating factor receptor signaling

280 ction, and surface expression of granulocyte-macrophage colony-stimulating factor receptor; all three

281 itment to the Flt3 locus vs GM-CSF-alpha and macrophage-colony-stimulating factor receptor loci.

282 Granulocyte-macrophage colony-stimulating factor-receptor-alpha expr

283 Granulocyte-macrophage colony-stimulating factor-receptor-alpha was

284 ted and expression of CSF2RB and granulocyte-macrophage colony-stimulating factor-responsive cells we

285 l lamina propria leukocytes with granulocyte-macrophage colony-stimulating factor resulted in high le

286 ed in vitro to recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) (1 ng/mL

287 Using recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) as a mod

288 GVAX pancreas, granulocyte-macrophage colony-stimulating factor-secreting allogenei

289 recently described population of granulocyte macrophage colony-stimulating factor-secreting cells of

290 d does not induce hyperactivated granulocyte macrophage colony-stimulating factor signaling or increa

291 chemokine (C-C motif) ligand 9, granulocyte-macrophage colony-stimulating factor, soluble tumor necr

292 tope, in a setting that includes granulocyte macrophage colony-stimulating factor-stimulated macropha

293 A isoform 121, bone morphogenetic protein 7, macrophage colony-stimulating factor, stromal cell-deriv

294 2 in PMN-MDSCs was controlled by granulocyte-macrophage colony-stimulating factor, through the activa

295 d the immunomodulatory adjuvants granulocyte-macrophage colony-stimulating factor, Toll-like receptor

296 rentiation induced by GM-CSF, did not affect macrophage-colony-stimulating factor-triggered different

297 intracellular calcium levels and granulocyte macrophage-colony-stimulating factor, tumor necrosis fac

298 The Csf1r locus encodes the receptor for macrophage colony-stimulating factor, which controls the

299 eosarcoma who were given inhaled granulocyte-macrophage colony-stimulating factor with first pulmonar

300 d progenitor hypersensitivity to granulocyte-macrophage colony-stimulating factor with myeloid cell d